The Modern Management of Gout: A Fresh Look at an Age-old Disease


For patients with moderate or moderate-severe inflammatory bowel disease (IBD), therapeutic options are limited to immunosuppressive therapy or biologic therapy with anti-TNFα agents. Although these can be effective, a significant proportion of patients with IBD are primary non-responders to anti-TNFα therapy, while more than one-half of responders experience loss of response or suffer side effects. Therefore, there is a clearly defined unmet need for novel treatments with different targets, ideally that are more ‘GI selective’. Clinical data available suggest that integrin inhibitors could offer one such option in the future.

This symposium will review current best practice and unmet needs, and the information which underpins the rationale for integrin inhibition. The current clinical evidence will be discussed, focusing on how these agents may be part of future clinical management of IBD.

Target Audience

The educational design of this activity addresses the needs of gastroenterologists and nurses involved in the treatment of patients with IBD.